Ann: Appendix 4C - quarterly, page-3

I would be interested to know what are TIS doing in R&D and clinical to expend $408K? Maybe this is 'preparation of response' so not paying consultants via shares but cash?

it would also be most welcome if TIS could share the modelling data; but I believes there are no data and this falls to a 'what if' category of model.
"Expert health economics modelling indicates that VitroGro® ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care."